Menu
Close
We revolutionise the discovery and development of bispecific antibody drug conjugates (bsADCs) to find the right treatment for any type of cancer.
Our Solution
Bispecific ADCs (bsADCs) have the potential to revolutionise ADCs as dual targeting enables improved cell selectivity. Our technology allows us to quickly design and test new bsADCs with complex structures and diverse target and payload combinations.
The discovery of new bsADCs is held back by an inability to rapidly generate and screening new therapeutic candidates. Valink builds whole libraries of drug candidates in days from a variety of components, including antibody fragments and small molecules.
Using our unique discovery platform, we can improve ADC processing. This allows us to build and develop unprecedented therapies in solid tumours and beyond.
We target solid tumours with bispecific antibody-drug conjugates. By aiming at two markers at once, we can improve effects and more accurately differentiate between malignant and healthy tissues.
Contact Us
United States
Valink Therapeutics Inc
50 Milk Street,
16th floor,
Boston,
MA 02109
United Kingdom
Valink Therapeutics Ltd
Imperial I-Hub,
84 Wood Lane,
London,
W12 0BZ
Message sent successfully.
Oops, something happened. Please try again.
United Kingdom
Valink Therapeutics Ltd
Imperial I-Hub,
84 Wood Lane,
London,
W12 0BZ
United States
Valink Therapeutics Inc
50 Milk St.,
16th floor,
Boston,
MA 02109
.png)
